Daily Cosmetic Research Analysis
Analyzed 20 papers and selected 3 impactful papers.
Summary
Advances span aesthetic dermatology and safety science: a 3D bioprinted full-thickness human skin model shows promise for predictive toxicology and cosmetic safety testing; a pediatric randomized trial supports adding 308‑nm excimer laser to tacrolimus plus compound glycyrrhizin for facial/neck vitiligo; and a large retrospective cohort suggests delayed repair of orbital blowout fractures achieves outcomes equivalent to early surgery.
Research Themes
- Alternative-to-animal testing and bioprinted human skin models
- Pediatric vitiligo therapeutics and repigmentation strategies
- Craniofacial trauma timing and outcomes in orbital fracture repair
Selected Articles
1. Development of a 3D bioprinted human skin model for predictive toxicology.
The authors engineered a full-thickness human skin construct by 3D bioprinting dense type I collagen with dermal fibroblasts and keratinocytes and showed biologically appropriate responses to established irritant and sensitizer controls. The model is reproducible and suitable for early-stage screening of topically applied compounds, supporting cosmetic safety assessment and reduction of animal use.
Impact: Provides a standardized, biomimetic human skin platform that can streamline predictive toxicology and cosmetic safety testing amid global shifts away from animal testing.
Clinical Implications: Enables earlier, more human-relevant screening of irritation and sensitization, potentially improving risk assessment and accelerating safe product development.
Key Findings
- A dense type I collagen bioink with fibroblasts and keratinocytes produced a full-thickness construct with dermal/epidermal features and relevant extracellular matrix.
- The model responded appropriately to established irritant and sensitizer controls, supporting predictive toxicology use.
- 3D bioprinting enabled precise, standardized architecture and reproducibility suitable for early-stage screening.
Methodological Strengths
- Use of high-concentration collagen I to enhance mechanical and biomimetic properties
- Validation with established irritant and sensitizer positive controls
Limitations
- Lacks quantitative head-to-head performance benchmarking against gold-standard in vitro or in vivo tests
- No vascular, immune, or adnexal components included, which may limit physiological fidelity
Future Directions: Incorporate immune/melanocyte components, barrier function metrics, and validate against clinical irritation/sensitization datasets to align with regulatory test guidelines.
Three-dimensional (3D) cultures represent an advanced approach for mimicking the architecture and cellular complexity of human tissues, providing a valuable alternative to conventional two-dimensional models. In particular, 3D bioprinting enables the generation of precise, standardized and biomimetic tissue constructs, with controlled spatial organization. The aim of the study was to design a novel 3D bioprinted full-thickness human skin model 3D protocol able to replicate human skin layers. The model is based on a high-concentration type I collagen bioink combined with dermal fibroblasts and keratinocytes, in which the use of dense collagen I enhances the mechanical properties and biomimetic features of the construct, providing dermal and epidermal contributions, and a physiologically relevant extracellular matrix. The skin like tissue (SLT) obtained was evaluated using established irritant and sensitizer controls, demonstrating its ability to respond to chemically induced stimuli without implying quantitative performance comparisons. Overall, this 3D skin model provides a biologically relevant and reproducible platform for early-stage testing of topically applied compounds, with potential applications in cosmetic safety assessment, drug screening, and alternative in vitro testing strategies.
2. Combination Therapy with 308-nm Excimer Laser, Compound Glycyrrhizin, and Tacrolimus for Pediatric Facial and Cervical Vitiligo.
In a randomized pediatric study (n=112), adding 308‑nm excimer laser twice weekly to oral compound glycyrrhizin and 0.03% topical tacrolimus increased overall efficacy (89.53% vs 70.51%), accelerated initial repigmentation by about 1 week, and shifted repigmentation patterns toward mixed types, with few self-limited adverse events. Findings support integrating excimer laser into facial/neck vitiligo management.
Impact: Provides randomized evidence in children for a practical combination regimen that improves efficacy and speed of repigmentation in cosmetically sensitive areas.
Clinical Implications: Supports adding 308‑nm excimer laser to tacrolimus-based regimens for pediatric facial/neck vitiligo to improve response and reduce psychosocial burden.
Key Findings
- Overall efficacy was higher with combination therapy (89.53%) than controls (70.51%) (p<0.05).
- Initial repigmentation occurred earlier with excimer laser (face 3.12±0.45 weeks; neck 3.74±0.44 weeks) versus controls (face 4.08±0.50; neck 4.54±0.51; both p<0.05).
- Adverse events were rare (3.57%) and self‑limited.
- Repigmentation pattern shifted toward mixed type (65.12%) versus predominantly follicular in controls (57.69%).
Methodological Strengths
- Randomized two‑arm design with pediatric population
- Objective assessment of efficacy, time to repigmentation, and pattern analysis
Limitations
- Single-center study with 16‑week treatment period; durability beyond 16 weeks not assessed
- Blinding not described; potential performance and detection bias
Future Directions: Assess long-term durability, quality-of-life outcomes, and head-to-head comparisons with NB‑UVB; explore optimization of laser dosing schedules.
BACKGROUND: Vitiligo is a common acquired depigmenting disorder in pediatric dermatology. Facial and cervical involvement is particularly distressing due to cosmetic disfigurement, leading to psychosocial impairment in children and significant psychological burden for parents. Safe and effective treatment strategies to halt disease progression and promote repigmentation are urgently needed. OBJECTIVE: To evaluate the clinical efficacy, onset of repigmentation, safety, and repigmentation patterns of 308-nm excimer laser combined with oral compound glycyrrhizin and topical 0.03% tacrolimus in children with facial and cervical vitiligo. METHODS: A total of 112 pediatric patients were randomized into two groups: treatment group (n=56, 86 lesions) received oral compound glycyrrhizin, topical 0.03% tacrolimus, plus 308-nm excimer laser twice weekly for 16 weeks; control group (n=56, 78 lesions) received compound glycyrrhizin and tacrolimus only. Clinical efficacy, time to initial repigmentation, adverse events, and repigmentation patterns (marginal, follicular, mixed) were assessed. RESULTS: The overall efficacy rate was significantly higher in the treatment group (89.53%) than in controls (70.51%) (p<0.05). Initial repigmentation occurred earlier in the treatment group (face: 3.12±0.45 weeks; neck: 3.74±0.44 weeks) compared with controls (face: 4.08±0.50 weeks; neck: 4.54±0.51 weeks, both p<0.05). Adverse events were rare (3.57%) and self-limited. Repigmentation patterns differed: treatment lesions showed predominantly mixed repigmentation (65.12%), whereas controls were mainly follicular (57.69%). CONCLUSION: Combination therapy with 308-nm excimer laser, compound glycyrrhizin, and 0.03% tacrolimus is safe and effective for pediatric facial and cervical vitiligo, providing faster repigmentation, higher efficacy, and distinct repigmentation patterns compared with medical therapy alone.
3. Comparison of Treatment Outcomes Between Early and Delayed Primary Repair of Orbital Blowout Fractures: A Single-Center Study.
In 172 adults with orbital blowout fractures, delayed primary repair performed ≥4 weeks after injury achieved equivalent final outcomes in EOM motility, enophthalmos (0.23 mm vs 0.23 mm), diplopia resolution by 12 months, and complication rates compared with early (≤4 weeks) repair. Operative time was similar, supporting delayed repair as an effective option for patients with persistent diplopia or late enophthalmos.
Impact: Challenges the presumption that early repair is necessary by showing noninferiority of delayed repair across functional, cosmetic, and neurosensory outcomes.
Clinical Implications: Allows flexibility in surgical timing without compromising outcomes, facilitating patient selection and resource allocation for BOF repair.
Key Findings
- Preoperatively, early group had worse EOM motility (-0.93 vs -0.49; P=0.005), while late group had greater enophthalmos (1.77 vs 1.33 mm; P=0.006).
- Final outcomes were similar for EOM motility (-0.12 vs -0.04; P=0.164) and enophthalmos (0.23 mm vs 0.23 mm; P>0.999).
- Residual diplopia resolved in all patients by 12 months (mean recovery ~65 days in both groups; P=0.997).
- Operative time, infraorbital hypesthesia rates, and complications did not differ between early and delayed repair.
Methodological Strengths
- Relatively large single-center cohort (n=172) with comprehensive functional and sensory endpoints
- Direct comparison of early (≤4 weeks) versus delayed (≥4 weeks) repair with statistical testing
Limitations
- Retrospective design with potential selection and confounding biases
- Nonrandomized timing; factors influencing delayed surgery may not be fully controlled
Future Directions: Prospective studies to validate noninferiority, define indications for delayed repair, and evaluate patient-reported cosmetic outcomes.
OBJECTIVES: To compare clinical outcomes between early (≤4 wk) and late (≥4 wk) surgical repair of orbital blowout fractures (BOF) in adults. METHODS: A retrospective review was conducted on 172 adults undergoing primary orbital BOF repair. Patients were categorized into early (n=123) and late (n=49) repair groups. Preoperative and postoperative outcomes were compared, including extraocular muscle (EOM) motility, enophthalmos, diplopia, infraorbital hypesthesia, operative time, and complications. RESULTS: Preoperative assessments revealed that patients in the early repair group exhibited worse EOM motility (-0.93 versus -0.49; P=0.005), whereas those in the late repair group presented with greater enophthalmos (1.77 versus 1.33 mm; P=0.006). Both groups demonstrated significant postoperative improvements, resulting in similar final outcomes for EOM motility (-0.12 versus -0.04; P=0.164) and enophthalmos (0.23 mm versus 0.23 mm; P>0.999). Residual diplopia resolved in all patients by 12 months (mean recovery: 64.57 versus 64.65 d; P=0.997). Infraorbital hypesthesia rates (1.6% versus 2.0%; P=0.851) and recovery times (74.00 versus 69.50 d; P=0.882) were comparable between groups. There were no significant differences in operative time (46.54 versus 46.45 min; P=0.984) or incidence of complications-including new diplopia, sensory deficits, or haematoma-between early and delayed repair. CONCLUSIONS: Delayed BOF repair conducted after 4 weeks achieved equivalent functional, cosmetic, and neurosensory outcomes compared with early intervention, with no increase in operative risks. Delayed repair remains a viable and effective option for patients presenting with persistent diplopia or late-onset enophthalmos.